Physician profile
Mark Lawton
NPI 1497707053
$6,789.71
in general payments reported to CMS, 2019-2025
30 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $601 · 2021: $882 · 2022: $1,132 · 2023: $620 · 2024: $1,252 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841 · Travel and Lodging: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,841.28 |
| Travel and Lodging | $874.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,148.22 | 2019-2025 | Aveir, Gallant, Aptivue |
| Abiomed | $887.63 | 2020-2025 | Impella |
| Medtronic, INC. | $731.69 | 2021-2024 | Micra, Attain Command + Surevalve, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $576.25 | 2019-2023 | Watchman Access System, Accolade Sr, Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $340.51 | 2019-2020 | |
| Atricure, INC. | $329.28 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $311.30 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $157.24 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $147.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $137.69 | 2021-2025 | Eliquis |
| Edwards Lifesciences Corporation | $132.92 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Shockwave Medical, INC | $120.95 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $117.46 | 2021 | |
| Cardiva Medical, INC. | $97.88 | 2021-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.10 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $67.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $67.69 | 2021 | |
| Inari Medical, INC. | $61.68 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cvrx, INC. | $58.50 | 2021-2023 | Barostim Neo System |
| Stryker Corporation | $47.32 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $30.33 | 2024-2025 | Wegovy |
| Pfizer INC. | $21.09 | 2021 | |
| Astellas Pharma US INC | $20.68 | 2021 | |
| Davol INC. | $19.20 | 2024 | |
| Alnylam Pharmaceuticals INC. | $16.49 | 2024 | Amvuttra |
| Esperion Therapeutics, INC. | $15.62 | 2021 | |
| Irhythm Technologies, INC. | $14.99 | 2024 | Zio Monitor, Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2025 | |
| Arbor Pharmaceuticals, INC. | $13.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lawton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.